Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Tegsedi for the Treatment of Polyneuropathy of hATTR Amyloidosis

Drug Name

Tegsedi™ (inotersen)

Developers

Ionis Pharmaceuticals

Therapy Class

Anti-sense oligonucleotide

Product Description

Inhibitor of human transthyretin (TTR) protein synthesis

Current Indication

Polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis

Market Sector

Genetics

Development Status

Approved in the US, Europe, and Canada
Expand
Close
Close
Close

Go Top